Journal article
Advanced stage melanoma therapies: Detailing the present and exploring the future
Critical reviews in oncology/hematology, Vol.133, pp.99-111
01/2019
DOI: 10.1016/j.critrevonc.2018.11.002
PMID: 30661664
Abstract
Metastatic melanoma therapies have proliferated over the last ten years. Prior to this, decades passed with only very few drugs available to offer our patients, and even then, those few drugs had minimal survival benefits. Many treatment options emerged over the last ten years with diverse mechanisms of action. Further, combination regimens have demonstrated superiority over monotherapy, especially for targeted agents. Each therapeutic combination possesses different advantages and side effect profiles. In this review, we outline the United States Food and Drug Administration–approved melanoma treatment agents and therapies currently in clinical development, focusing on combination approaches.
Details
- Title: Subtitle
- Advanced stage melanoma therapies: Detailing the present and exploring the future
- Creators
- Chelsea Luther - Henry Ford HospitalUmang Swami - University of IowaJun Zhang - University of Iowa Hospitals and ClinicsMohammed Milhem - University of Iowa Hospitals and ClinicsYousef Zakharia - University of Iowa Hospitals and Clinics
- Resource Type
- Journal article
- Publication Details
- Critical reviews in oncology/hematology, Vol.133, pp.99-111
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.critrevonc.2018.11.002
- PMID
- 30661664
- ISSN
- 1040-8428
- eISSN
- 1879-0461
- Language
- English
- Date published
- 01/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359845102771
Metrics
18 Record Views